CLDX Q4 2024 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-71.6% YoY

Gross Profit

$356,00030.3% margin

Operating Income

-$56M-4768.3% margin

Net Income

-$47M-4007.8% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

-63.2%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$792M

Total Liabilities

$45M

Stockholders' Equity

$747M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$4M	-71.6%
Gross Profit	$356,000	-$26M	+101.4%
Operating Income	-$56M	-$48M	-17.6%
Net Income	-$47M	-$43M	-8.7%

Revenue Segments

Grant

$4M100%

Service

$8,0000%